S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Gritstone bio, Inc. (GRTS)
Chart Events
Performance Outlook
| Previous Close | 1.9500 |
| Open | 2.0100 |
| Bid | 1.8600 x 4000 |
| Ask | 1.9400 x 3200 |
| Day's Range | 1.8200 - 2.0100 |
| 52 Week Range | 1.7100 - 14.4200 |
| Volume | |
| Avg. Volume | 1,268,751 |
| Market Cap | 131.896M |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0740 |
| Earnings Date | Mar 11, 2022 - Mar 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.67 |
- GlobeNewswire
Gritstone to Participate in H.C. Wainwright Global Investment Conference
EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer of Gritstone, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which is being held virtually and in-person from May 23-26, 2022. The fireside chat will be available on-demand begi
- Simply Wall St.
Are Institutions Heavily Invested In Gritstone bio, Inc.'s (NASDAQ:GRTS) Shares?
The big shareholder groups in Gritstone bio, Inc. ( NASDAQ:GRTS ) have power over the company. Generally speaking, as a...
- GlobeNewswire
CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines against viruses expected over the next 18 months -- -- Recent presentations reinforce expertise in vaccine design and delivery and potential of Gritstone’s platform technologies in oncology and infectious diseases -- -- Cash, cash equivalents, marketable securities and restricted cash of $186.8 millio
